Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis

Regeneron Pharmaceuticals, Inc. (REGN) rose 0.63% to USD 656.01 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.

REGN last closed at USD 651.91; the session ranged USD 654.05–667.5 on volume of 708,319 shares. Market capitalization is $68.78B, with a 52-week range of USD 541–821.11 (NMS). Source: Nexqual, July 25, 2026 at 01:12 UTC.

Key Statistics (as of July 25, 2026 at 01:12 UTC)

Technical Analysis (REGN)

Nexqual's technical model rates REGN "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.

Analyst Ratings (REGN)

Wall Street analysts rate REGN "Buy" based on 26 analysts, with a mean price target of USD 819.25 (range USD 641–1,000), per Nexqual as of July 25, 2026 at 01:12 UTC.

Earnings (REGN)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 01:12 UTC.

Financials & Fundamentals (REGN)

Source: Nexqual, July 25, 2026 at 01:12 UTC.

Financial Health Score (REGN)

Nexqual rates Regeneron Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 01:12 UTC.

Ownership (REGN)

Source: Nexqual, July 25, 2026 at 01:12 UTC.

Leadership (REGN)

Regeneron Pharmaceuticals, Inc. is led by Leonard S. Schleifer (age 72), Co-Founder, President, CEO & Co-Chairman, per Nexqual as of July 25, 2026 at 01:12 UTC.

Major Backers & Investors (REGN)

Notable institutional backers of Regeneron Pharmaceuticals, Inc. include Dodge & Cox Inc., Invesco, JPMorgan, according to Nexqual as of July 25, 2026 at 01:12 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 01:12 UTC.

From Regeneron Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-04)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition, central to the ongoing work of RGC is the portfolio of collaborations with over 150 academic and clinical collaborators around the world, including the University of Colorado, Geisinger Health System, Mayo Clinic, University of Pennsylvania, UCLA Medical Center, UK Biobank, University of Oxford, and the University of Cambridge.
• The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and Good Clinical Practice requirements ("GCPs"), which establish standards for recruiting for, conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible, representative, and accurate, and that the rights, safety, and well-being of study participants are protected.
• Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities.
• In-licensing a late-stage GLP-1/GIP agonist enables us to study combinations with our products and product candidates in order to address muscle loss and potentially other comorbidities of obesity, such as cardiovascular diseases, diabetes, and liver conditions.

Partnerships

• In January 2025, RGC entered into an agreement with Truveta Inc. pursuant to which RGC will sequence exomes and conduct genotyping and imputation of up to ten million de-identified consented volunteers using biospecimens provided by Truveta health system members across the United States.
• Hansoh In July 2025, our license agreement with Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights outside of mainland China, Hong Kong, and Macau for HS-20094 (a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical development in China) became effective.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.